Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
复制标题
DOI：
10.3390/jcm11236882
复制
发表时间：
2022-11-22
影响因子：
3.9
通讯作者：
Miwa, Hiroto
中科院分区：
文献类型：
--
作者：
Tomita, Toshihiko;Fukui, Hirokazu;Morishita, Daisuke;Mori, Sumire;Oshima, Tadayuki;Shinzaki, Shinichiro;Miwa, Hiroto
患有静止期炎症性肠病（IBD）的患者经常遭受肠易激综合征（IBS-D）样症状，例如腹痛或大便不规则。在这里，我们评估雷莫司琼，5-羟色胺3型（5-HT 3）受体拮抗剂，对IBS-D样症状的静止期IBD患者的影响。70例符合罗马III IBS-D诊断标准的静止期IBD患者随机分为雷莫司琼组（5 μg; n = 35）和安慰剂组（n = 35），口服，每日1次，共4周。主要终点是总体IBS-D样症状缓解总体评估的应答率。还评价了腹痛/不适缓解和排便习惯改善的应答率。在最终评估点，雷莫司琼组总体IBS-D样症状缓解的应答率（35.5%）显著高于安慰剂组（11.4%）（p = 0.037）。雷莫司琼组排便习惯改善的应答率（38.7%）显著高于安慰剂组（14.3%）（p = 0.028）。雷莫司琼组大便次数的减少显著大于安慰剂组（p = 0.044）。雷莫司琼可有效缓解静止期IBD患者的总体IBS-D样症状。
Patients with quiescent inflammatory bowel disease (IBD) frequently suffer diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms, such as abdominal pain or stool irregularities. Here, we assessed the effect of ramosetron, a serotonin type 3 (5-HT3) receptor antagonist, on IBS-D-like symptoms in patients with quiescent IBD. Seventy patients with quiescent IBD, who met the Rome III diagnostic criteria for IBS-D, were randomly assigned to receive either ramosetron (5 μg; n = 35) or a placebo (n = 35) orally once daily for 4 weeks. The primary endpoint was the responder rate for global assessment of relief from overall IBS-D-like symptoms. The responder rates for relief of abdominal pain/discomfort and improvement of bowel habits were also evaluated. The responder rate for relief from overall IBS-D-like symptoms at the final evaluation point was significantly higher in the ramosetron group (35.5%) than in the placebo group (11.4%) (p = 0.037). The responder rate for improvement of bowel habits was significantly higher in the ramosetron group (38.7%) than in the placebo group (14.3%) (p = 0.028). The reduction of stool frequency was significantly greater in the ramosetron group than in the placebo group (p = 0.044). Ramosetron is effective for relief of overall IBS-D-like symptoms in patients with quiescent IBD.
登录
查看更多内容
影响因子：
29.4
作者：
Kilpatrick LA;Labus JS;Coveleskie K;Hammer C;Rappold G;Tillisch K;Bueller JA;Suyenobu B;Jarcho JM;McRoberts JA;Niesler B;Mayer EA
通讯作者：
Mayer EA
影响因子：
4.6
作者：
Fukui H;Oshima T;Tanaka Y;Oikawa Y;Makizaki Y;Ohno H;Tomita T;Watari J;Miwa H
通讯作者：
Miwa H
影响因子：
3.5
作者：
Lee, K. J.;Kim, N. Y.;Rhee, P. L.
通讯作者：
Rhee, P. L.
DOI：
10.1073/pnas.0804812105
发表时间：
2008-10-28
影响因子：
11.1
作者：
Sokol, Harry;Pigneur, Benedicte;Langella, Philippe
通讯作者：
Langella, Philippe
DOI：
10.1254/jjp.69.205
发表时间：
1995-11-01
期刊：
JAPANESE JOURNAL OF PHARMACOLOGY
影响因子：
--
作者：
MIYATA, K;YAMANO, M;AKUZAWA, S
通讯作者：
AKUZAWA, S